Company · founded 1991
BioScience Laboratories (United States)
Bozeman, United States · biosciencelabs.com
- Citations, last 5 years
- 9
- Works, last 5 years
- 4
- h-index
- 37
- Scientists listed
- 0
- Grants since 2016
- 188
Grants received
2020–2021 · contract · N01
NIAID Preclinical Development Support: Essential Core Activities
Timothy Fouts · BioScience Laboratories (United States) · funded by National Institutes of Health
2020 · contract · N01
Comprehensive Resources for HIV Microbicides and Biomedical Prevention: Quality Assurance/ Quality Control (QA/QC)
Maria Ferrari · BioScience Laboratories (United States) · funded by National Institutes of Health
2020–2021 · contract · N01
Comprehensive Resources for HIV Microbicides and Biomedical Prevention: Material Receipt, Storage, Shipping and Inventory
Maria Grazia Ferrari · BioScience Laboratories (United States) · funded by National Institutes of Health
2019–2020 · contract · N01
DEVELOPMENT AND TESTING OF MESSAGING TO DRIVE ADOPTION AND USE OF HIV PREVENTION PRODUCTS AMONG YOUNG, URBAN AND PER-URBAN SOUTH AFRICAN WOMEN
Pal Ranajit · BioScience Laboratories (United States) · funded by National Institutes of Health
2019–2020 · contract · N01
OVINE MODEL AND VAGINAL MICROBIOME SUPPORT FOR HIV NONVACCINE BIOMEDICAL PREVENTION PRODUCT DEVELOPMENT.
Glenn Swartz · BioScience Laboratories (United States) · funded by National Institutes of Health
2019 · contract · N01
Contract Orientation and Kickoff Meeting (POP: 8/14/2019-9/13/2019)
(Contact) · BioScience Laboratories (United States) · funded by National Institutes of Health
2019–2020 · contract · N01
STATISTICAL AND PHARMACOMETRIC MODELING SUPPORT FOR HIV NON-VACCINE BIOMEDICAL PREVENTION PRODUCT DEVELOPMENT
Ranajit Pal · BioScience Laboratories (United States) · funded by National Institutes of Health
2019–2020 · contract · N01
Ethnographic Expertise for Enhancing Study Drug Adherence in HIV Prevention Trials
Ranajit Pal · BioScience Laboratories (United States) · funded by National Institutes of Health
2019–2021 · contract · N01
Development and Testing of Messaging to Drive Adoption and Use of HIV Prevention Products Among Young, Urban and Peri-Urban South African Women
Maria Grazia Ferrari · BioScience Laboratories (United States) · funded by National Institutes of Health
2019–2022 · contract · N01
Evaluation of the Immunogenicity and Efficacy of HIV-1 Clade A BG505 SOSIP.664 Env Glycoprotein Trimer Vaccine Administered with TLR Agonist or Alum Adjuvants
Ranajit Pal · BioScience Laboratories (United States) · funded by National Institutes of Health
2019–2020 · contract · N01
MATERIAL RECEIPT, STORAGE, SHIPPING AND INVENTORY
Glenn Swartz · BioScience Laboratories (United States) · funded by National Institutes of Health
2019–2023 · contract · N01
cGMP Manufacturing of Glycopeptide Immunogen Nanoparticle Vaccine
Timothy Fouts · BioScience Laboratories (United States) · funded by National Institutes of Health
2019–2020 · contract · N01
COMPREHENSIVE RESOURCES FOR HIV MICROBICIDES AND BIOMEDICAL PREVENTION: QUALITY AND RISK MANAGEMENT
Pal Ranajit · BioScience Laboratories (United States) · funded by National Institutes of Health
2019–2023 · contract · N01
Manufacture of a Vaccine Targeting Frame-Shift Mutations Characteristic of Tumors with Microsatellite Instability
Beth Tebeau · BioScience Laboratories (United States) · funded by National Institutes of Health
2019–2021 · contract · N01
Characterization of the Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of a Candidate HIV Prevention Drug in Rhesus Macaques
Pal Ranajit · BioScience Laboratories (United States) · funded by National Institutes of Health
2019–2024 · contract · N01
cGMP Production of a HCMV gag (P4) prototype HIV vaccine candidate
Timothy Fouts · BioScience Laboratories (United States) · funded by National Institutes of Health
2019–2024 · contract · N01
Characterization of the Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of a Candidate HIV Prevention Drug in Rhesus Macaques
Peter Silvera · BioScience Laboratories (United States) · funded by National Institutes of Health
2019–2021 · contract · N01
Manufacture of a Vaccine Targeting Frame-Shift Mutations Characteristic of Tumors with Microsatellite Instability
Beth Tebeau · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2022 · contract · N01
Expansion and Characterization of Relevant Simian Immunodeficiency Virus (SIV) Stocks for Use in Drug Assays or Repeat, Low-Dose Challenge Studies in Rhesus Macaques
Peter Silvera · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2019 · contract · N01
Comprehensive Resources for HIV Microbicides and Biomedical Prevention: Quality Assurance/ Quality Control (QA/QC)
Ranajit Pal · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2028 · contract · N01
Task V23: Storage and product formulation (Formulation of gD2 Nanoemulsion Drug Product)
Tim Fouts · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2019 · contract · N01
Ethnographic Expertise for Enhancing Study Drug Adherence in HIV Prevention Trials
Ranajit Pal · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2023 · contract · N01
NIAID Preclinical Development Support: Adjuvants for HIV-1 Vaccines
Thomas Vancott · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2025 · contract · N01
Next Generation Development of Broadly Neutralizing HIV Antibodies for Prevention
Timothy Fouts · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2019 · contract · N01
EXPANSION AND CHARACTERIZATION OF RELEVANT SIMIAN IMMUNODEFICIENCY VIRUS (SIV) STOCKS FOR USE IN DRUG ASSAYS OR REPEAT, LOW-DOSE CHALLENGE STUDIES IN RHESUS MACAQUES
Ranajit Pal · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2028 · contract · N01
Task V04: Malaria Vaccine Stability Study
Tmothy Fouts · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2028 · contract · N01
Task V25: PROCESS DEVELOPMENT FOR VACCINE CANDIDATES INCLUDING SARS-COV-2
Tim Fouts · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2019 · contract · N01
Comprehensive Resources for HIV Microbicides and Biomedical Prevention: Quality Assurance/ Quality Control (QA/QC)
Ranajit Pal · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2028 · contract · N01
Task V30: GMP Manufacturing of WNV Vaccine
Wang Hong · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2023 · contract · N01
IGF::OT::IGF NIAID Preclinical Development Support- cGMP Manufacturing of PGT121 and PGDM1400 Antibodies
John Mascola · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2028 · contract · N01
Task V26: The Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of services spanning product development planning and
Tim Fouts · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2021 · contract · N01
Synthesize and Produce HIV-1 Envelope Glycopeptide Immunogen Nanoparticle Vaccine(s)
Thomas Vancott · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2019 · contract · N01
Essential Core Activities: NIAID Preclinical Development Support
Thomas Vancott · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2028 · contract · N01
Task V23: Storage and product formulation (Formulation of gD2 Nanoemulsion Drug Product)
Tim Fouts · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2028 · contract · N01
Task V04: Malaria Vaccine Stability Study
Tmothy Fouts · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2020 · contract · N01
Synthesize and Produce HIV-1 Envelope Glycopeptide Immunogen Nanoparticle Vaccine(s)
Thomas Vancott · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2022 · contract · N01
EVALUATION OF THE IMMUNOGENICITY AND EFFICACY OF HIV-1 CLADE C OLIGOMERIC ENVELOPE PROTEIN DELIVERED WITH ADVAX DELTA INULIN ADJUVANT BY INTRAMUSCULAR AND INTRAPULMONARY ROUTES
Ranajit Pal · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2020 · contract · N01
NIAID Preclinical Development Support: Synthesize and Produce HIV-1 Envelope Glycopeptide Immunogen Nanoparticle Vaccine(s)
Thomas Vancott · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2019 · contract · N01
Ovine Model and Vaginal Microbiome Support for HIV Non-vaccine Biomedical Prevention Product Development
Glenn Swartz · BioScience Laboratories (United States) · funded by National Institutes of Health
2018–2021 · contract · N01
Preclinical Gap-Filling Services: Studies to Assess Interactions Between Dapivirine and Vaginally-Applied, Over-The-Counter Products
Maria Grazia Ferrari · BioScience Laboratories (United States) · funded by National Institutes of Health
